MCID: HRP008
MIFTS: 16

Herpes Simiae

Categories: Rare diseases

Aliases & Classifications for Herpes Simiae

MalaCards integrated aliases for Herpes Simiae:

Name: Herpes Simiae 53

Classifications:



Summaries for Herpes Simiae

MalaCards based summary : Herpes Simiae The drugs rituximab and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney.

Related Diseases for Herpes Simiae

Symptoms & Phenotypes for Herpes Simiae

Drugs & Therapeutics for Herpes Simiae

Drugs for Herpes Simiae (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 2,Phase 3,Not Applicable 174722-31-7 10201696
2
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
3
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 134678-17-4 60825
4
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
5
Oseltamivir Approved Phase 4,Phase 3,Phase 2,Not Applicable 204255-11-8, 196618-13-0 65028
6
Tacrolimus Approved, Investigational Phase 4,Not Applicable 104987-11-3 445643 439492
7
Mycophenolic acid Approved Phase 4 24280-93-1 446541
8
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
9
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
10
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
11
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 143491-57-0 60877
12
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
13
Peginterferon alfa-2b Approved Phase 4,Phase 3,Not Applicable 99210-65-8, 215647-85-1
14
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 142340-99-6 60871
15
Ethiodized oil Approved, Investigational Phase 4,Phase 2,Not Applicable 8008-53-5
16
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 21645-51-2
17
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
18
Infliximab Approved Phase 4 170277-31-3
19
Abacavir Approved, Investigational Phase 4,Not Applicable 136470-78-5 65140 441300
20
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
21
Thymalfasin Approved, Investigational Phase 4,Phase 1,Phase 2 62304-98-7
22
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
23
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
24
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
25
Ibuprofen Approved Phase 4 15687-27-1 3672
26
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
27
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
28
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
29
Ledipasvir Approved Phase 4,Phase 2,Phase 3 1256388-51-8 67505836
30
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
31 Dolutegravir Approved Phase 4 1051375-16-6 54726191
32
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
33
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 143 6006
34
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
36
Adefovir Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106941-25-7
37
Clevudine Investigational Phase 4,Phase 3,Phase 2 163252-36-6
38
Lactitol Investigational Phase 4 585-86-4 3871
39
Tenofovir Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147127-20-6 464205
40 Atorvastatin Calcium Phase 4 134523-03-8
41
Bilirubin Phase 4 635-65-4 5280352
42 Analgesics Phase 4,Phase 3
43 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 1,Phase 2
47 gamma-Globulins Phase 4,Phase 3,Phase 1,Phase 2
48 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Aluminum phosphate Phase 4
50 Cyclooxygenase Inhibitors Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 641)
# Name Status NCT ID Phase Drugs
1 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
2 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
3 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
4 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
5 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
6 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4 Entecavir + Tenofovir (MDR group)
7 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
8 Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
9 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4 Mycophenolate Mofetil;Tacrolimus
10 Banlangen Granules Anti-seasonal Influenza Study Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
11 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
12 Twinrix Alternative Schedule Study Unknown status NCT00216229 Phase 4
13 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
14 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4 Telbivudine
15 Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude Unknown status NCT02523547 Phase 4 Cavir;Baraclude
16 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
17 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
18 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
19 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
20 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
21 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
22 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
23 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
24 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
25 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
26 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
27 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
28 Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy Unknown status NCT01928511 Phase 4 peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly;Nucleos(t)ide analogue therapy
29 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
30 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
31 TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA Completed NCT01732367 Phase 4 Lamivudine plus adefovir;Tenofovir
32 Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Completed NCT01788371 Phase 4 Telbivudine;Lamivudine
33 Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Completed NCT00371150 Phase 4 Entecavir
34 Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy Completed NCT02039362 Phase 4 Tenofovir DF
35 A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) Completed NCT02570191 Phase 4 Peginterferon alfa-2a
36 Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Completed NCT00662545 Phase 4 Entecavir with continued standard of care antiretroviral therapy;continued standard of care with tenofovir in addition to emtricitabine or lamivudine
37 A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program Completed NCT02791269 Phase 4 Peginterferon alfa-2a
38 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) Completed NCT00397540 Phase 4
39 Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules Completed NCT01259453 Phase 4
40 Long-term Study With Clevudine Completed NCT00558818 Phase 4 Clevudine
41 A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B Completed NCT00436163 Phase 4 Peginterferon alfa-2a
42 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. Completed NCT01519921 Phase 4 peginterferon alfa-2a [Pegasys]
43 Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects Completed NCT02202473 Phase 4 Lamivudine;Lamivudine+Oxymatrine Capsules
44 A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Completed NCT00393484 Phase 4 Entecavir;Lamivudine Placebo;Lamivudine;Entecavir Placebo
45 Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection Completed NCT00127959 Phase 4 tenofovir;emtricitabine;zidovudine;efavirenz
46 Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder Completed NCT01847430 Phase 4
47 Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection Completed NCT02479880 Phase 4 Tenofovir DF
48 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Completed NCT01327547 Phase 4 Maraviroc;Placebo
49 A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) Completed NCT02604823 Phase 4 Peginterferon alfa-2a
50 Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA Completed NCT00637663 Phase 4 Entecavir;Lamivudine

Search NIH Clinical Center for Herpes Simiae

Genetic Tests for Herpes Simiae

Anatomical Context for Herpes Simiae

MalaCards organs/tissues related to Herpes Simiae:

41
Liver, Testes, Kidney, T Cells, Bone, Bone Marrow, B Cells

Publications for Herpes Simiae

Articles related to Herpes Simiae:

# Title Authors Year
1
Latency of Herpes Simiae (B virus) in rabbits. ( 177039 )
1975
2
Recovery of herpes simiae (B virus) from both primary and latent infections in rhesus monkeys. ( 177038 )
1975
3
Heterogeneity in Herpes simiae (B virus) and some antigenic relationships in the herpes group. ( 4375486 )
1974

Variations for Herpes Simiae

Expression for Herpes Simiae

Search GEO for disease gene expression data for Herpes Simiae.

Pathways for Herpes Simiae

GO Terms for Herpes Simiae

Sources for Herpes Simiae

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....